We report on the use of one-dimensional photonic crystals to detect clinically relevant concentrations of ERBB2/neu/Her2 in cell lysates. ERBB2 is a pivotal breast cancer biomarker and targetable oncogenic driver associated with aggressive breast cancer subtypes. To quantitate soluble ERBB2, we developed an optical platform that combines label-free and fluorescence detection modes. Such platform makes use of a sandwich assay in which the one-dimensional photonic crystals sustaining Bloch surface waves are tailored with a monoclonal antibody for highly specific biological recognition (BSW biochip). In a second step, a second antibody to ERBB2 quantitatively detects the bound analyte. The strategy of the present approach takes advantage of the combination of label-free and fluorescence techniques, making bio-recognition more robust and sensitive. In the fluorescence operation mode, the platform can attain the limit of detection 0.3 ng/mL (1.5 pM) for ERBB2 in cell lysates. Such resolution meets the international guidelines and recommendations (15 ng/mL) for diagnostic ERBB2 assays that in the future may help to more precisely assign therapies counteracting cancer cell proliferation and metastatic spread.

Detection of soluble ERBB2 in breast cancer cell lysates using a combined label-free/fluorescence platform based on Bloch surface waves / Sinibaldi, Alberto; Sampaoli, Camilla; Danz, Norbert; Munzert, Peter; Sibilio, Leonardo; Sonntag, Frank; Occhicone, Agostino; Falvo, Elisabetta; Tremante, Elisa; Giacomini, Patrizio; Michelotti, Francesco. - In: BIOSENSORS & BIOELECTRONICS. - ISSN 0956-5663. - STAMPA. - 92:(2017), pp. 125-130. [10.1016/j.bios.2017.02.012]

Detection of soluble ERBB2 in breast cancer cell lysates using a combined label-free/fluorescence platform based on Bloch surface waves

SINIBALDI, ALBERTO;OCCHICONE, AGOSTINO;MICHELOTTI, Francesco
2017

Abstract

We report on the use of one-dimensional photonic crystals to detect clinically relevant concentrations of ERBB2/neu/Her2 in cell lysates. ERBB2 is a pivotal breast cancer biomarker and targetable oncogenic driver associated with aggressive breast cancer subtypes. To quantitate soluble ERBB2, we developed an optical platform that combines label-free and fluorescence detection modes. Such platform makes use of a sandwich assay in which the one-dimensional photonic crystals sustaining Bloch surface waves are tailored with a monoclonal antibody for highly specific biological recognition (BSW biochip). In a second step, a second antibody to ERBB2 quantitatively detects the bound analyte. The strategy of the present approach takes advantage of the combination of label-free and fluorescence techniques, making bio-recognition more robust and sensitive. In the fluorescence operation mode, the platform can attain the limit of detection 0.3 ng/mL (1.5 pM) for ERBB2 in cell lysates. Such resolution meets the international guidelines and recommendations (15 ng/mL) for diagnostic ERBB2 assays that in the future may help to more precisely assign therapies counteracting cancer cell proliferation and metastatic spread.
1D photonic crystals; Bloch surface waves; Breast cancer; ERBB2; Optical biosensors; SK-BR 3; Biotechnology; Biophysics; Biomedical Engineering; Electrochemistry
01 Pubblicazione su rivista::01a Articolo in rivista
Detection of soluble ERBB2 in breast cancer cell lysates using a combined label-free/fluorescence platform based on Bloch surface waves / Sinibaldi, Alberto; Sampaoli, Camilla; Danz, Norbert; Munzert, Peter; Sibilio, Leonardo; Sonntag, Frank; Occhicone, Agostino; Falvo, Elisabetta; Tremante, Elisa; Giacomini, Patrizio; Michelotti, Francesco. - In: BIOSENSORS & BIOELECTRONICS. - ISSN 0956-5663. - STAMPA. - 92:(2017), pp. 125-130. [10.1016/j.bios.2017.02.012]
File allegati a questo prodotto
File Dimensione Formato  
Sinibaldi_Detection_2017.pdf

Open Access dal 10/02/2019

Note: https://doi.org/10.1016/j.bios.2017.02.012
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Creative commons
Dimensione 780.5 kB
Formato Adobe PDF
780.5 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/945894
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 33
social impact